Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HARMONYL vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Hypertension (FDA-approved),Off-label: Management of opioid withdrawal symptoms, treatment of attention deficit hyperactivity disorder (ADHD), and reduction of menopausal hot flashes
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Hepatic metabolism via glucuronidation and sulfation; CYP450 enzymes not significantly involved.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
95% bound primarily to albumin and alpha-1-acid glycoprotein
~10-20% bound to plasma proteins (primarily albumin).
1.2–1.8 L/kg (mean 1.5 L/kg); indicates extensive tissue distribution
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 75%; IM: 90%
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
GFR ≥ 30 m L/min: no adjustment. GFR 15-29 m L/min: reduce to 12.5 mg once daily. GFR < 15 m L/min: not recommended.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 12.5 mg once daily. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Weight < 30 kg: not established. Weight ≥ 30 kg: 0.5 mg/kg orally once daily, up to 25 mg maximum.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Initiate at 12.5 mg once daily; increase cautiously to 25 mg once daily based on tolerability and renal function.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Abrupt discontinuation may cause rapid rise in blood pressure (rebound hypertension) and symptoms of sympathetic overactivity (e.g., nervousness, agitation, headache). This is particularly dangerous in patients on high doses or concurrent beta-blocker therapy.
None
Rebound hypertension upon abrupt withdrawal; caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure; may cause sedation and dry mouth; use caution in patients with history of depression.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to clonidine or any component; use with MAO inhibitors (hypertensive crisis risk); noncompliant patients who may abruptly discontinue therapy (risk of rebound hypertension).
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) due to risk of hypertensive crisis. Limit alcohol intake as it may enhance orthostatic hypotension.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
FDA Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and cleft palate due to folate antagonism. Second and third trimesters: risk of oligohydramnios, fetal renal dysfunction, and premature closure of ductus arteriosus if used after 30 weeks gestation.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Contraindicated during breastfeeding. M/P ratio: not determined. Excreted in human milk in low concentrations, but potential for serious adverse reactions in nursing infants, including hemolytic anemia and kernicterus due to sulfonamide component.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No established safe dose. Drug should be avoided during pregnancy. If unavoidable, use lowest effective dose for shortest duration. Trimethoprim component may require dose reduction due to increased glomerular filtration rate in pregnancy, but specific adjustment not validated. Sulfamethoxazole dose unchanged.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Harmonyl is a brand name for deserpidine, a Rauwolfia alkaloid used as an antihypertensive. It depletes catecholamines and serotonin from central and peripheral nerve endings. Onset of action is 1-2 weeks. Avoid in patients with history of depression, peptic ulcer, or pheochromocytoma. Monitor for bradycardia and hypotension. May cause extrapyramidal symptoms. Use with caution with MAOIs; avoid concurrent use.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take this medication exactly as prescribed, usually once daily.,Do not stop taking this medication abruptly; sudden withdrawal can cause severe hypertension.,You may experience dizziness or drowsiness; avoid driving or operating machinery until you know how the medication affects you.,Avoid alcohol while taking this medication.,Report any signs of depression, unusual mood changes, or difficulty sleeping to your doctor.,If you have a history of stomach ulcers, inform your doctor before starting this medication.,Keep all appointments for blood pressure monitoring.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HARMONYL vs ALDOMET, answered by our medical review team.
HARMONYL is a Antihypertensive that works by Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HARMONYL and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HARMONYL is: 25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HARMONYL and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HARMONYL is classified as Category C. FDA Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and cleft palate due to folate antagonism. Second and third trimesters: . ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.